SCHEDULE: Fairmount Funds Sells Cogent Bio Shares

Fairmount Funds Management LLC reported a block sale of 3.5 million shares of Cogent Biosciences, Inc. common stock at $36.40 per share, reducing its beneficial ownership to 9.9%.

Summary

• Fairmount Funds Management LLC and its affiliates filed an Amendment No. 9 to their Schedule 13D for Cogent Biosciences, Inc.
• The reporting persons now beneficially own 16,261,918 shares of Common Stock, representing 9.9% of the outstanding class.
• This ownership includes 5,503,418 shares of Common Stock and 10,758,500 shares of Common Stock issuable upon conversion of 43,034 shares of Series A Convertible Preferred Stock.
• On January 22, 2026, Fairmount Healthcare Fund II L.P. executed a block trade, selling 3,500,000 shares of Common Stock at a price of $36.40 per share.
• The total outstanding Common Stock of Cogent Biosciences, Inc. as of January 22, 2026, is 164,264,062 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant block sale by a major institutional investor, which could signal reduced confidence or a strategic exit from a portion of the holding. While the fund retains a substantial stake, the sale itself is generally viewed as a bearish signal in the short term.

Positives

• Fairmount Funds Management LLC and its affiliates maintain a significant beneficial ownership stake of 9.9% in Cogent Biosciences, Inc., indicating continued interest.
• The sale was executed at a specific price of $36.40 per share, providing liquidity for the fund.

Negatives

• Fairmount Healthcare Fund II L.P. sold a substantial block of 3,500,000 shares, which could be interpreted as a reduction in conviction or a strategic portfolio adjustment.
• A large block sale by a significant institutional investor can sometimes put downward pressure on the stock price in the short term.

Risks

• The beneficial ownership limitation of 9.9% on the conversion of Series A Preferred Stock means that a portion of the Series A Preferred Stock owned by Fund II (totaling 67,414 shares, with only 43,034 counted towards the limit) cannot be immediately converted into Common Stock if it would exceed this threshold, potentially restricting the fund's flexibility.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Cogent Biosciences, Inc. or the reporting persons regarding the company's future performance or strategic direction.

Industry Context

A significant block sale by a major institutional investor like Fairmount Funds Management LLC can signal a shift in investment strategy or portfolio rebalancing within the biotechnology or pharmaceutical sector. While the fund maintains a substantial stake, such a transaction is often closely watched by other investors for potential implications regarding the company's valuation or future prospects, especially in a sector sensitive to investor sentiment and capital flows.

Stakeholder Impact

• Shareholders: The sale of a large block of shares by a significant investor could lead to increased selling pressure and potentially a decrease in share price, impacting existing shareholders.
• Company Management: May need to address investor concerns or questions arising from a major shareholder's partial divestment.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Cogent Biosciences, Inc. or the reporting persons beyond the reported transaction.

Key Dates

Recommendation

The reporting person, Fairmount Funds Management LLC, executed a substantial block sale of 3.5 million shares, which typically introduces short-term selling pressure and can be perceived as a negative signal by the market. However, the fund retains a significant beneficial ownership of 9.9% of Cogent Biosciences, Inc., indicating continued strategic interest and a non-complete divestment. This suggests the sale might be a portfolio rebalancing or profit-taking rather than a complete loss of confidence in the company's long-term prospects. Investors should maintain a 'hold' position to observe how the market absorbs this block sale and await further company-specific news or changes in institutional sentiment before adjusting their investment strategy.

Keywords

Cogent Biosciences, Fairmount Funds, Schedule 13D, Common Stock, Series A Preferred Stock, block trade, beneficial ownership, institutional investor, stock sale, equity